Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts.
This study examined the effects of long-term treatments with the angiotensin-converting enzyme inhibitor, enalapril, and the calcium antagonist, amlodipine, on the morphologic changes, progressive left ventricular dysfunction, and gene expression of the ryanodine receptor (RyR) and phospholamban (PLN) in dilated cardiomyopathy. From the ages of 5 through 20 weeks, dilated cardiomyopathic hamsters, BIO53.58 (BIO), and control hamsters, F1b, orally received either enalapril or amlodipine. Cardiac function was assessed by echocardiography. At the age of 20 weeks, the collagen volume fractions were analyzed by the stereologic method. RyR and PLN messenger RNAs (mRNAs) were examined by Northern blot in the amlodipine group. In BIO, the reduction of left ventricular percentage of fractional shortening was attenuated in the enalapril group (p < 0.05) and amlodipine group (p < 0.001), and the increase in the collagen volume fraction and the loss of myocytes were suppressed in the amlodipine group compared with the untreated group. RyR mRNA level decreased in BIO (p < 0.01) compared with F1b, but PLN mRNA level was unchanged. RyR and PLN mRNA levels were unaffected by the treatment with amlodipine. Enalapril and amlodipine prevent progressive remodeling and reduce cardiac dysfunction in BIO. Amlodipine prevents fibrosis and cell death without modifying RyR and PLN mRNA levels in BIO.
Watanabe
M
M
Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Kawaguchi
H
H
Onozuka
H
H
Mikami
T
T
Urasawa
K
K
Okamoto
H
H
Watanabe
S
S
Abe
K
K
Kitabatake
A
A
D017311:Amlodipine / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002135:Calcium-Binding Proteins / Q000235:genetics / Q000378:metabolism; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006224:Cricetinae; D004195:Disease Models, Animal; D004656:Enalapril / Q000494:pharmacology*; D005109:Extracellular Matrix / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006321:Heart / Q000187:drug effects / Q000502:physiology; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D051381:Rats; D019837:Ryanodine Receptor Calcium Release Channel / Q000235:genetics / Q000378:metabolism; D014665:Vasodilator Agents / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects; D000099211:Phospholamban
D017311:Amlodipine; D000806:Angiotensin-Converting Enzyme Inhibitors; D002118:Calcium; D002121:Calcium Channel Blockers; D002135:Calcium-Binding Proteins; D004656:Enalapril; D019837:Ryanodine Receptor Calcium Release Channel; D014665:Vasodilator Agents; D000099211:Phospholamban